The estimated Net Worth of Kamal Adawi is at least $1.42 Million dollars as of 4 March 2024. Mr Adawi owns over 12,784 units of Exagen Inc stock worth over $738,559 and over the last 5 years he sold XGN stock worth over $61,649. In addition, he makes $620,300 as CFO & Corp. Sec. at Exagen Inc.
Mr has made over 4 trades of the Exagen Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 12,784 units of XGN stock worth $24,417 on 4 March 2024.
The largest trade he's ever made was selling 12,784 units of Exagen Inc stock on 4 March 2024 worth over $24,417. On average, Mr trades about 2,637 units every 35 days since 2019. As of 4 March 2024 he still owns at least 243,749 units of Exagen Inc stock.
You can see the complete history of Mr Adawi stock trades at the bottom of the page.
Kamal Adawi M.S., MBA is the CFO & Corp. Sec. at Exagen Inc.
As the CFO & Corp. Sec. of Exagen Inc, the total compensation of Mr MBA at Exagen Inc is $620,300. There are 2 executives at Exagen Inc getting paid more, with Fortunato Rocca having the highest compensation of $1,627,720.
Mr MBA is 42, he's been the CFO & Corp. Sec. of Exagen Inc since . There are 12 older and 1 younger executives at Exagen Inc. The oldest executive at Exagen Inc is James Tullis, 72, who is the Independent Director.
Kamal's mailing address filed with the SEC is C/O EXAGEN INC., 1261 LIBERTY WAY, VISTA, CA, 92081.
Over the last 5 years, insiders at Exagen Inc have traded over $8,628,989 worth of Exagen Inc stock and bought 556,568 units worth $6,283,309 . The most active insiders traders include James L L Tullis, Bio Exagen, L.P.H.I.G. Gpii... und Jeffrey Thomas Elliott. On average, Exagen Inc executives and independent directors trade stock every 48 days with the average trade being worth of $109,189. The most recent stock trade was executed by John Aballi on 16 May 2024, trading 40,401 units of XGN stock currently worth $77,570.
exagen diagnostics, inc. is a patient focused, discovery driven, clia-certified, cap-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of rheumatology and autoimmune diseases. committed to personalized medicine, our avise tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. for more information on our company, please visit www.exagen.com. for more information on avise testing services, please visit www.avisetest.com.
Exagen Inc executives and other stock owners filed with the SEC include: